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Black women bear the highest burden of human immunodeficiency virus (HIV) infection among US women. Tenofovir/emtric-
itabine HIV prevention trials among women in Africa have yielded varying results. Ideally, a randomized controlled trial (RCT) 
among US women would provide data for guidelines for US women’s HIV preexposure prophylaxis use. However, even among US 
black women at high risk for HIV infection, sample size requirements for an RCT with HIV incidence as its outcome are prohibi-
tively high. We propose to circumvent this large sample size requirement by evaluating relationships between HIV incidence and 
drug concentrations measured among participants in traditional phase 3 trials in high-incidence settings and then applying these 
observations to drug concentrations measured among at-risk individuals in lower-incidence settings, such as US black women. This 
strategy could strengthen the evidence base to enable black women to fully benefit from prevention research advances and decrease 
racial disparities in HIV rates.
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Randomized clinical trials (RCT) are the gold standard for 
establishing the causal effect of treatments in preventing disease. 
RCTs that use human immunodeficiency virus (HIV) serocon-
version as the outcome have been especially critical in determin-
ing an intervention’s efficacy in preventing HIV infection; one 
recent trial that influenced global policy was the demonstration 
that administration of antiretroviral therapy to the HIV-infected 
member of a serodiscordant couple reduces HIV transmission to 
the seronegative partner [1]. Recent trials have documented the 
efficacy of preexposure prophylaxis (PrEP) with antiretroviral 
agents in preventing HIV infection in specific high-risk groups 
and settings, such as men who have sex with men (MSM) or 
women and men in sub-Saharan Africa [2–7].
However, epidemiologic features of HIV infection present 
challenges to exclusive reliance on traditional RCTs for devel-
oping and implementing interventions to prevent HIV infec-
tion. Moreover, whereas RCTs provide valuable information 
concerning efficacy, their sometimes limited generalizability 
and uncertain effectiveness of the intervention when delivered 
in a nontrial setting can leave providers and public health prac-
titioners with substantial gaps in the information needed to 
inform clinical and public health.
RCTs that rely on HIV type 1 (HIV-1) seroconversion as an 
endpoint also require a substantial HIV incidence in the study 
population and/or very large numbers of participants to demon-
strate efficacy with statistical significance. However, ending the 
HIV epidemic will require extension of research findings to vul-
nerable populations, such as US black women, whose incidence, 
although substantially greater than that of white women, is not 
high enough to support a feasible RCT.
This article outlines current issues associated with testing bio-
medical prevention products in populations whose HIV inci-
dence is higher than in the general population but at a level where 
an RCT would require thousands of participants. We outline a 
strategy that incorporates use of drug concentrations and recog-
nized epidemiologic methods to estimate intervention effects.
THE PROBLEM
Women constitute more than half of people living with HIV 
worldwide and about one-quarter of those in the United States 
[8]. Whereas women throughout the world share heterosexual 
transmission as the most common acquisition mode for HIV, 
the epidemiologic context in which women acquire infection 
differs by geography. The HIV epidemic among young women 
in southern Africa is relatively generalized [9], but among US 
women, poverty, discrimination, and the effects of social forces 
on sexual networks have disproportionately concentrated HIV 
among blacks and Latinas [8, 10]. The Centers for Disease 
Control and Prevention estimates that the annual rate of new 
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more than an order of magnitude greater than among white 
women (3.4 per 100 000) [11]. RCTs of PrEP agents among 
women have typically been conducted in parts of Africa where 
the HIV incidence among women is exceptionally high (typi-
cally >3% annually), to yield enough new HIV cases to enable 
determination of product efficacy [2, 4, 5, 12]. The results of 
these studies have varied dramatically. For example, although 
tenofovir/emtricitabine (TDF/FTC) has prevented HIV infec-
tion among African women who took it consistently, it has 
failed to prevent infection in trials where adherence was low; 
efficacy estimates have ranged between 66% [4] and −4.4% [12].
Ideally, an RCT conducted among high-risk US women 
would provide the evidence base to support guidelines for 
US women’s use of PrEP. But such a study likely is not feasi-
ble: Despite the nation’s marked racial disparities in HIV rates, 
the absolute incidence of infection among US black women 
is substantially lower than among women in southern Africa. 
Although HIV rates are higher among the poor and in areas of 
the northeastern and southern United States, predicting which 
US black women will acquire infection remains difficult. A 
recent study enrolled US women at exceptionally high risk for 
HIV acquisition; their annual HIV incidence at 320 per 100 000 
person-years (95% confidence interval, 140–740 per 100 000 
person-years) was 5 times that of black women in the general 
US population [13]. However, even at that higher HIV inci-
dence, a 5-year RCT (with 10% loss to follow-up) would require 
a total of 10 000 participants to demonstrate the 44% efficacy of 
TDF/FTC (compared to placebo) seen, for example, in the pre-
exposure prophylaxis initiative (iPrEX) trial among MSM [3]. 
Studies comparing a new PrEP intervention with TDF/FTC as 
a control would need to be substantially larger, as the incidence 
in the TDF/FTC arm would be lower, even if TDF/FTC demon-
strates only modest efficacy.
PREVIOUSLY PROPOSED STRATEGIES
Solutions for this fundamental problem of fielding trials in 
lower-incidence settings have been proposed, but none suc-
cessfully ameliorates the need for exceedingly large sample 
sizes. One suggested approach, for example, is to use alterna-
tive outcomes as surrogates for HIV acquisition, such as trans-
mission rates of other sexually transmitted infections (STIs). 
However, although other STIs could potentially substitute for 
HIV as an evaluation outcome when condoms or behavioral 
interventions for HIV prevention are tested, other STIs are 
not in the pathway between HIV infection and antiretroviral 
agents that only prevent HIV infection and are an inadequate 
HIV surrogate in this setting. In 2 large studies of PrEP effi-
cacy, substantial reductions in HIV incidence were accompa-
nied by no change in STI incidence [6, 14].
Mathematical models are valuable for estimating the pop-
ulation impact and effectiveness or cost of implementing 
interventions to prevent HIV infection (see, eg, [15–17]) but 
are unable to determine product efficacy in individual patients 
and depend on reliable estimates of efficacy. Another potential 
approach is to generalize results of studies conducted in other 
parts of the world, such as sub-Saharan Africa, to women in 
lower- incidence regions. However, currently available interven-
tions for women, such as oral and topical PrEP, depend on high 
adherence, and dramatic variations in adherence among dif-
ferent African study populations have contributed to markedly 
different trial results and therefore substantially limit general-
izability [4, 5, 12, 18]. Moreover, social and contextual factors 
may further impact adherence, making it even more difficult 
to generalize results across cultures. It may be possible to esti-
mate efficacy by accounting for adherence in a per-protocol 
analysis [19]. Once the per-protocol effect is estimated, it can 
be mapped to the clinically relevant population of interest [20, 
21]. However, this strategy requires that important differences 
between the trial and target populations that affect generaliza-
bility are measured and correctly modeled [20].
Unfortunately, all of these approaches require information 
that is typically unavailable, such as the causes of nonadherence 
that also affect the outcome, and the presence and extent of rela-
tionships between covariates and nonadherence.
OUR PROPOSAL
We propose to circumvent the low-incidence-setting require-
ment for large sample sizes by evaluating the relationship 
between HIV incidence and drug concentrations measured 
among participants in traditional phase 3 trials conducted in 
high-incidence settings, and then applying these observations 
to drug concentrations measured among individuals in low-
er-incidence settings. The steps would be as follows: First, con-
duct a phase 3 trial in a setting where the results are needed for 
the benefit of the population in which the study will be con-
ducted and, as in similar past trials, HIV incidence is the out-
come and incidence among women exceeds 3000 per 100 000 
per year [2, 4, 5, 7, 12, 18]. Measure drug concentrations at 
multiple time points among all participants as well as effect 
modifiers of the relationship between drug concentration and 
incidence (such as anal sex, STI coinfection, types of sexual 
partnerships, known polymorphisms that affect drug metab-
olism). In addition to estimating the intent-to-treat effect, use 
the various levels of observed drug concentration to estimate 
the per-protocol treatment effects [19]. We assume that we 
have measured the set of variables that jointly determine drug 
concentrations and HIV risk. Second, in the lower-incidence 
setting, enroll participants from the at-risk population into an 
open-label trial with measurement of drug concentrations and 
the same effect modifiers as previously outlined in the phase 3 
trial in the high- incidence setting. Standardize the per-protocol 
treatment effects from the phase 3 higher-incidence trial to this 
lower-incidence setting, using established methods for general-
izability [20, 22]. As before, we assume that we have measured 
and controlled for the relevant effect measure modifiers whose 
distribution differs in the 2 studies. Under these additional 
assumptions, one can compute the causal effect of the treat-
ment on HIV infection in the lower incidence setting. While the 
trial in the lower-incidence setting would require considerably 
fewer participants than an RCT, it would need many more par-
ticipants than the usual early-phase pharmacokinetic studies: 
sufficient participants would be required to yield a represent-
ative range of samples to estimate concentrations in the target 
population with adequate precision and to accurately measure 
variables that modify the effect. It is also critical that the enroll-
ees be highly representative of the population at risk, in contrast 
to typical pharmacokinetic studies that may be conducted in 
low-risk populations.
DISCUSSION
We propose a strategy for estimating the efficacy of HIV preven-
tion interventions in lower-incidence populations without con-
ducting large RCTs in these populations. The method requires 
collection of drug concentration data, analyzing its relationship 
to efficacy, and then standardizing these results to drug concen-
trations observed in lower-incidence settings. These results will 
enable estimation of the efficacy of prevention in these settings 
and provide considerably more data to enable treatment and 
policy recommendations than is currently available.
This strategy relies on several assumptions. First, we assume 
there is a relationship between observed drug concentrations 
and efficacy. Second, we assume the relationship between 
drug concentration and efficacy is similar in the higher- and 
lower-incidence populations. Thus, potential effect modifiers, 
such as frequency and distribution of anal sex, must be con-
sidered and assessed. Initial determinations of the relationship 
between concentration and efficacy must be performed in a 
population where HIV incidence is high enough to make such 
measurement feasible; otherwise, the relationship cannot be 
determined.
In addition, we assume the observed drug concentrations 
accurately reflect typical concentrations that are consistently 
achieved. This assumption would be violated if, for example, a 
participant on daily oral medication only takes the drug before 
levels are measured but otherwise does not. Incident infection 
in this participant would be inaccurately associated with a high 
drug level. Additional use of electronic monitoring of access to 
medication bottles (eg, MEMSCap) could improve the perfor-
mance of drug concentration data. Of note, directly observed 
therapy, such as long-acting injections, substantially reduces 
this problem. Long-acting agents may enable more accurate 
estimation of the relationship between drug concentration 
and HIV acquisition. Because clinicians will directly adminis-
ter these drugs, pharmacokinetic assessments will allow more 
accurate estimation of drug concentrations at the time of HIV 
infection, which may be separated from the drug sampling time 
by weeks. Analyses of the relationship would not require the 
assumption that the patient has continued adherence at the 
same level as when the drug concentration was sampled, a likely 
assumption for evaluating adherence/acquisition relationships 
with short-acting oral therapy.
Limitations of the proposed strategy include the assumptions 
outlined above, as well as the logistical concerns and increased 
expense associated with measurement of drug concentrations. 
But these costs would be modest compared to those of a huge 
traditional RCT in a lower-incidence setting. Although use 
of existing specimens from completed or ongoing prevention 
trials could theoretically obviate the need for conducting a de 
novo phase 3 trial in a high-incidence setting, even when such 
specimens exist, they are generally not collected frequently 
enough and not accompanied by enough information (eg, tim-
ing of specimen relative to drug administration) to allow the 
proposed analysis. But addition of the appropriate samples and 
measurements to a planned efficacy study in a high-incidence 
setting would be an efficient way to reduce costs and gather the 
most relevant data.
Another limitation of our suggested approach is that the 
phase 3 trial still requires enrollment of a study population with 
a substantial HIV incidence. In addition, ethical considerations 
now require use of an effective drug in the control arm instead 
of a placebo. Use of an effective drug in the control arm would 
decrease the HIV incidence in this arm, which would reduce 
the likelihood of observing an effect of the experimental drug—
and mandate a larger total sample size (or a noninferiority trial 
design) for determination of efficacy.
In summary, we propose a strategy that leverages the rela-
tionship between drug concentrations and efficacy obtained 
from phase 3 HIV incidence studies to derive estimates of effi-
cacy and effectiveness in lower-incidence populations, such as 
US black women, among whom randomized phase 3 trials are 
likely to be prohibitively large. A next step to assess the perfor-
mance of the method we propose includes Monte Carlo sim-
ulation using currently available pharmacokinetic, incidence, 
and other clinical data. Pursuit of this strategy will be impor-
tant to further develop the evidence base to enable disenfran-
chised populations to benefit from the advances in prevention 
research and eliminate racial disparities in HIV infection rates.
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